LBA2 TALENTACE: A phase III, open-label, randomized study of on-demand transarterial chemoembolization (TACE) combined with atezolizumab + bevacizumab (Atezo+Bev) or on-demand TACE alone in patients with systemically untreated, intermediate-to-high burden unresectable hepatocellular carcinoma (uHCC)
Jiahong Dong(Jilin University), M. Kudo(Kindai University), Jie Zhu(Anhui Medical University), Tingting Peng(Sun Yat-sen University), M. Zhao(Sun Yat-sen University), Junying Song(Chinese Academy of Sciences), Makoto Ueno(Kanagawa Prefectural Hospital Organization), Guangsen Han(Zhengzhou University), Yaojun Zhang(Sun Yat-sen University), Shanzhi Gu(Central South University), Junjie Liu(North China Electric Power University), Ran Liu(Southeast University), Fang Liu(Guangzhou University of Chinese Medicine), Bai Li(Beijing Union University), Hao Hu(Unknown), Kezhi Lin(Wenzhou Medical University), Zhenhua Lin(Yanbian University), Satoshi Ogasawara(Kyoto University), Zongwen Liu(The University of Sydney)
Cited by 37
Related Papers
Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial
|Clinical Cancer Research|2020|576
Milestones in Autonomous Driving and Intelligent Vehicles: Survey of Surveys
|IEEE Transactions on Intelligent Vehicles|2022|485
An approach to position sensorless drive for brushless DC motors
|IEEE Transactions on Industry Applications|1991|448